Cite
HARVARD Citation
Gerlach, M. et al. (n.d.). TUB-010, a novel antibody drug conjugate with reduced nonspecific toxicity profile based on Tub-tag technology widens the therapeutic window of targeting CD30. European journal of cancer. pp. S27-. [Online].